BMS-191095 hydrochloride | 166095-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: BMS-191095 hydrochloride
• 英文别名: (3R-trans)-4-[4-Chloro-N-(1H-imidazole-2ylmethyl)phenylamino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile, HCl salt；(3R,4S)-4-[4-chloro-N-(1H-imidazol-2-ylmethyl)anilino]-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile;hydrochloride
• CAS: 166095-95-0
• 化学式: C₂₂H₂₁ClN₄O₂*ClH
• 分子量: 445.348
• InChiKey: TZLMTXNZECPICU-JUDYQFGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.64
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  85.2
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (3R,4S)-4-[4-chloro-N-(1H-imidazol-2-ylmethyl)anilino]-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile 以98的产率得到BMS-191095 hydrochloride
  参考文献：
  名称：

  4-Arylamino-benzopyran and related compounds

  摘要：

  具有以下化学式和药学上可接受的盐的化合物，其中X为烷基，Y为单键，-CH₂-，-C（O）-，-O-，-S-或-N（R⁸）-，其中R⁸为氢，烷基，卤代烷基，芳基，芳基烷基，环烷基或（环烷基）烷基，而R¹到R⁷如本文所定义。这些化合物具有钾通道激活活性，因此可用作心血管药物等用途。

  公开号：

  EP0648758A1

文献信息

• 4-Arylamino-benzopyran and related compounds
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0648758A1

  公开（公告）日：1995-04-19

  Compounds having the formula and pharmaceutically acceptable salts thereof wherein X is alkyl, Y is a single bond, -CH₂-, -C(O)-, -O-, -S- or -N(R⁸)- where R⁸ is hydrogen, alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl or (cycloalkyl)alkyl, and R¹ to R⁷ are as defined herein. These compounds have potassium channel activating activity and are useful, therefore for example, as cardiovascular agents.

  具有以下化学式和药学上可接受的盐的化合物，其中X为烷基，Y为单键，-CH₂-，-C（O）-，-O-，-S-或-N（R⁸）-，其中R⁸为氢，烷基，卤代烷基，芳基，芳基烷基，环烷基或（环烷基）烷基，而R¹到R⁷如本文所定义。这些化合物具有钾通道激活活性，因此可用作心血管药物等用途。
• Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
  申请人：Herlands Louis

  公开号：US20070026079A1

  公开（公告）日：2007-02-01

  Provided are methods of increasing K ATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.
• Modulation of Hypothalamic Atp-Sensitive Potassium Channels
  申请人：Rossetti Luciano

  公开号：US20090012067A1

  公开（公告）日：2009-01-08

  Provided are methods of increasing K ATP activity in the hypothalamus of a mammal, methods of reducing glucose production and peripheral blood glucose levels in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, and methods of increasing glucose production and peripheral blood glucose levels in a mammal.